Alliance A151804: Establishment of a National Biorespository to Advance Studies of Immune-Related Adverse Events
Aims: The purpose of this study is to gather information about why do some patients experience serious side effects from immunotherapies,how can we identify these patients, and how to prevent, reduce, and treat these side effects more effectively.
Diagnosis: Any cancer
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH20-292
Sponsor: Alliance
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
Carevive: Real World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute yelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring
Aims: The purpose of this study is to gather information about symptoms of patients underoing treatment.
Diagnosis: Breast, lung, myeloma, leukemia, or ovarian cancer
Principal Investigator: Nicklas Pfanzelter, MD
IRB Approval Number: EH21-244
Sponsor: Carevive Systems, Inc.
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes
Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer
Aims: The purpose of this research is to learn how best to perform and use gene testing in cancer patients
Diagnosis: any patient with solid tumor
Principal Investigator: Bruce Brockstein and Karen Kaul
IRB Approval Number: EH20-392
Sponsor: NorthShore
Contact: For further information, please contact Annette Sereika at 847.570.2735
Open to Enrollment: Yes
EAY131: Molecular Analysis for Therapy Choice (MATCH)
Aims: This study will look at assigning treatment for patients whose cancer has become worse after standard treatment. Patients will have a genomic analysis of their tumor which will direct appropriate targeted therapy.
Diagnosis: any solid tumor
Principal Investigator: Robert Marsh, MD
IRB Approval Number: EH15-387
Sponsor: ECOG-ACRIN/NCI
Contact: For further information, please contact Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes (limited)